drugset / Trial / NCT03514420
Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
Timeline
- Start
- 2018-06-15
- Primary completion
- 2019-07-30
- Completion
- 2019-08-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vupanorsen | Unknown | 20 mg | Subcutaneous |